Advertisement

Picture Berlin Partner Top News Noah Labs Raises $3m AI Telemonitoring 650x100px
Person › Details

Jean-Marc Hyvelin (Stalicla S.A.)

Hyvelin, Jean-Marc (Stalicla 202002 COO)

 

Organisation Organisation Stalicla S.A.
Products Product drug development
  Product 2 neurology
     

Stalicla S.A.. (2/3/20). "Press Release: Swiss Biotech Stalicla Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A". Geneva.

STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) - including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay - today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M). The round was supported by a consortium of Swiss, European and US private equity and Biotech experienced investors. STALICLA will use the proceeds of this second tranche to move its lead ASD precision medicine candidate - STP1 - into Phase 1b clinical trials and its second program, STP2, into IND enabling pre-clinical studies.

Funds will also support the scale-up of STALICLA’s first in class Neurodevelopmental Disorder focused discovery platform. This new round of financing brings the company’s total equity financing to USD 18.4M over the last 30 months.

“I am honored and proud that existing Shareholders and new investors are consolidating their trust in STALICLA’s unique assets and growth potential – STALICLA is the first ever precision medicine company in the Neurodevelopmental Disorder space. Leveraging on its cutting-edge NDD precision medicine platform, STALICLA has demonstrated its capacity to execute rapidly on its development plan by bringing STP1 towards clinical stage in less than 3 years. The proceeds of these financing series will support STALICLA’s sustained operations towards a drastic shift in the field of NDDs.” – said Lynn Durham, CEO & Founder


About STALICLA

STALICLA is a near clinical Company developing a first in class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDDs). First focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need.

In its Geneva and Barcelona units, STALICLA has assembled a world class team of experienced drug developers and computational biologists. The company is recognized as a disruptive key player in the NDD space, using its DEPIv3 innovative systems biology AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments.
It is the first time that such technologies have been utilized within the field of neurodevelopment with the potential to change the direction of the specialty.

In less than 3 years, the STALICLA platform has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identifying two additional subgroups.

STALICLA’s first therapeutic package - STP1 - addresses this first distinct subgroup of ASD patients estimated to 1.5 - 2M people in the EU and North America. Clinical entry for STP1 is planned first half 2020.

To support its platform and pipeline development, STALICLA has developed a network of top tier research and clinical partners in the US.

STALICLA is currently scaling up DEPIv3 to advance new pipelines for additional groups of patients with NDDs.


Contacts

Lynn Durham
communication@stalicla.com
0041 (0) 22 545 12 42


STALICLA

Headquarters: Geneva, Switzerland
Website: stalicla.com
CEO: Lynn Durham
Employees: 18
Organization: PRI

   
Record changed: 2020-02-09

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px



To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x300px




» top